Geron Corporation
USE OF A JANUS KINASE INHIBITOR AND A TELOMERASE INHIBITOR FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS
Last updated:
Abstract:
Aspects of the disclosure include methods for treating a myeloproliferative neoplasm. Methods according to certain embodiments include co-administering to a subject a Janus kinase (JAK) inhibitor and a telomerase inhibitor comprising an oligonucleotide and a lipid moiety linked to the 5' and/or 3' end of the oligonucleotide. Methods for inducing apoptosis of a myeloproliferative neoplasm cell by contacting the cell with an amount of a JAK inhibitor and a telomerase inhibitor sufficient to induce apoptosis are also described. Compositions having a JAK inhibitor and a telomerase inhibitor for practicing the subject methods are also provided.
Status:
Application
Type:
Utility
Filling date:
3 Nov 2020
Issue date:
2 Sep 2021